Medical Crossfire : Renal Cell Carcinoma in an Era of Rapid Discovery : Key Questions
WebcastFaculty
OVERVIEW
Medical Crossfire : Renal Cell Carcinoma in an Era of Rapid Discovery : Key Questions is organized by Physicians Education Resource, LLC (PER) and would be held during Jan 30, 2017 - Jan 30, 2018.
The target audience for this medical event for oncologists, surgical oncologists, radiation oncologists, and urologists who treat patients with renal cell carcinoma (RCC). Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare providers who are interested in the care of patients with RCC may also participate. This CME Conference has been approved with a maximum of 1.5 AMA PRA Category 1 Credits.
Conference Objectives are :
• Explain targeted and immunotherapeutic mechanistic approaches to overcome anti-angiogenic resistance in the management of RCC.
• Describe evidence-based approaches that inform optimized sequencing of current and emerging strategies for RCC.
• Discuss proactive measures to manage and mitigate treatment-related side effects associated with approaches for advanced RCC.
• Critically evaluate recent clinical trial data in the context of the established evidence guiding individualized treatment planning for patients with advanced RCC.
Additional details will be posted as soon as they are available.
The target audience for this medical event for oncologists, surgical oncologists, radiation oncologists, and urologists who treat patients with renal cell carcinoma (RCC). Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare providers who are interested in the care of patients with RCC may also participate. This CME Conference has been approved with a maximum of 1.5 AMA PRA Category 1 Credits.
Conference Objectives are :
• Explain targeted and immunotherapeutic mechanistic approaches to overcome anti-angiogenic resistance in the management of RCC.
• Describe evidence-based approaches that inform optimized sequencing of current and emerging strategies for RCC.
• Discuss proactive measures to manage and mitigate treatment-related side effects associated with approaches for advanced RCC.
• Critically evaluate recent clinical trial data in the context of the established evidence guiding individualized treatment planning for patients with advanced RCC.
Additional details will be posted as soon as they are available.
SPECIALITIES
Oncology
Quick Links